Alternate-Day Buprenorphine Administration. Phase VIII - 9
Phase 2
Completed
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00000227
- Lead Sponsor
- University of Vermont
- Brief Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Opioid withdrawal Opioid agonist effects Dose choice Drug use
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of buprenorphine contribute to its efficacy in opioid-related disorders?
How does alternate-day buprenorphine administration compare to daily dosing in opioid addiction treatment?
Are there specific biomarkers that predict response to buprenorphine in opioid dependence?
What are the potential adverse events associated with buprenorphine and how can they be managed?
What combination therapies or alternative drugs show promise for opioid-related disorders alongside buprenorphine?
Trial Locations
- Locations (1)
Treatment Research Center
🇺🇸Burlington, Vermont, United States
Treatment Research Center🇺🇸Burlington, Vermont, United States